INDICATION
Rejoyn is a prescription digital therapeutic for the treatment of Major Depressive Disorder (MDD) symptoms as an adjunct to clinician-managed outpatient care for adult patients with MDD age 22 years and older who are on antidepressant medication. It is intended to reduce MDD symptoms.

SAFETY INFORMATION
Rejoyn is not intended to be used as a standalone therapy or a substitute for medication. Patients should continue their current treatment as directed.
Rejoyn does not monitor the patient’s symptoms or clinical status and cannot send or receive alerts or warnings to the prescriber. Patients should be clearly instructed that if they believe their depression is worsening or if they have feelings or thoughts of harming themselves or others, to contact a healthcare professional, dial 911 or go tothe nearest emergency room immediately.
‍
This webinar is selected by Osmind to be sponsored by Otsuka Precision Health, Inc. Speaker is a paid consultant of Otsuka.
The intended audience for this program is healthcare professionals involved in the treatment of patients with Major Depressive Disorder.

For more information about Rejoyn, including a copy of the Clinician Brief Summary, visit RejoynHCP.com